

7 March 2025

Incidence and Treatment of Breast Cancer

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions.

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) <5
- Abemaciclib + Fulvestrant <5
- Alpelisib + Fulvestrant <5
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide 40
- Aromatase Inhibitor as a single agent <5
- Atezolizumab <5
- Capecitabine as a single agent 18
- Carboplatin + Paclitaxel <5
- Elacestrant <5
- Eribulin as a single agent or in combination <5
- Everolimus + Exemestane <5
- Fulvestrant as a single agent 6
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) <5
- Palbociclib + Fulvestrant <5
- Parp Inhibitors (Olaparib/Talazoparib) <5
- Pembrolizumab <5
- Pertuzumab (Perteja) + Trastuzumab (Herceptin) <5
- Phesgo (Pertuzumab + Trastuzumab in a single injection) <5
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) <5
- Ribociclib + Fulvestrant <5
- Sacituzumab Govitecan <5
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 15
- Trastuzumab deruxtecan (Enhertu) 10
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel 13
- Trastuzumab emtansine (Kadcyla) 11

• Any other active systemic anti-cancer therapy

Abemaciclib	46
Palbociclib	39
Ribociclib	26
D-Phesgo	7
ECDPhesgo	19
EC/PC	<5
Epirubicin	<5
FEC	<5
Neratinib	<5

7 March 2025

Penbro+PC/EC	<5
Talazoparib	<5
Tucat/Cape/Trast	<5
Vinorelbine	<5

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable.

Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. How many patients have been treated for metastatic breast cancer in the past 3 months with the following systemic anti-cancer therapies:

- **Phesgo (Pertuzumab + Trastuzumab in a single injection)**
- **Pertuzumab (Perteja) + Trastuzumab (Herceptin)**
- **Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel**
- **Trastuzumab deruxtecan (Enhertu)**
- **Trastuzumab emtansine (Kadcyla)**

Belfast Trust is not able to answer this question, as the information is not available on the Regional Information System for Oncology and Haematology (RISOH)

3. If breast cancer is not treated at or within the Trust, where are patients referred?

Breast cancer is treated in all Health and Social Care Northern Ireland (HSCNI) Trusts.